Medigene AG Statistics
Total Valuation
Medigene AG has a market cap or net worth of 1.35 million. The enterprise value is -11.62 million.
| Market Cap | 1.35M |
| Enterprise Value | -11.62M |
Important Dates
The next estimated earnings date is Friday, August 15, 2025.
| Earnings Date | Aug 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 14.89M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.65% |
| Shares Change (QoQ) | +5.09% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 14.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.17 |
| PB Ratio | 0.06 |
| P/TBV Ratio | 0.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.68 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.73 |
Financial Position
The company has a current ratio of 2.39, with a Debt / Equity ratio of 0.13.
| Current Ratio | 2.39 |
| Quick Ratio | 2.22 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.17 |
| Interest Coverage | -28.34 |
Financial Efficiency
Return on equity (ROE) is -63.93% and return on invested capital (ROIC) is -34.49%.
| Return on Equity (ROE) | -63.93% |
| Return on Assets (ROA) | -27.15% |
| Return on Invested Capital (ROIC) | -34.49% |
| Return on Capital Employed (ROCE) | -69.20% |
| Revenue Per Employee | 91,703 |
| Profits Per Employee | -196,226 |
| Employee Count | 76 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.58% in the last 52 weeks. The beta is 0.91, so Medigene AG's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | +6.58% |
| 50-Day Moving Average | 2.09 |
| 200-Day Moving Average | 1.52 |
| Relative Strength Index (RSI) | 1.82 |
| Average Volume (20 Days) | 500 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medigene AG had revenue of 7.98 million and -17.07 million in losses. Loss per share was -1.35.
| Revenue | 7.98M |
| Gross Profit | 6.38M |
| Operating Income | -16.52M |
| Pretax Income | -16.74M |
| Net Income | -17.07M |
| EBITDA | -15.84M |
| EBIT | -16.52M |
| Loss Per Share | -1.35 |
Balance Sheet
The company has 15.03 million in cash and 2.73 million in debt, giving a net cash position of 12.30 million.
| Cash & Cash Equivalents | 15.03M |
| Total Debt | 2.73M |
| Net Cash | 12.30M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 21.07M |
| Book Value Per Share | 1.43 |
| Working Capital | 9.75M |
Cash Flow
In the last 12 months, operating cash flow was -15.19 million and capital expenditures -665,381, giving a free cash flow of -15.85 million.
| Operating Cash Flow | -15.19M |
| Capital Expenditures | -665,381 |
| Free Cash Flow | -15.85M |
| FCF Per Share | n/a |
Margins
Gross margin is 79.94%, with operating and profit margins of -207.04% and -213.98%.
| Gross Margin | 79.94% |
| Operating Margin | -207.04% |
| Pretax Margin | -209.76% |
| Profit Margin | -213.98% |
| EBITDA Margin | -198.51% |
| EBIT Margin | -207.04% |
| FCF Margin | n/a |
Dividends & Yields
Medigene AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.65% |
| Shareholder Yield | n/a |
| Earnings Yield | -1,265.95% |
| FCF Yield | -1,175.45% |
Stock Splits
The last stock split was on August 29, 2024. It was a reverse split with a ratio of 0.5.
| Last Split Date | Aug 29, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.5 |
Scores
Medigene AG has an Altman Z-Score of -22.41. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -22.41 |
| Piotroski F-Score | n/a |